Atai Life Sciences Comprehensive Income 2020-2024 | ATAI
Atai Life Sciences comprehensive income from 2020 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Atai Life Sciences Annual Comprehensive Income (Millions of US $) |
2023 |
$-19 |
2022 |
$-22 |
2021 |
$-8 |
2020 |
$6 |
2019 |
$-1 |
Atai Life Sciences Quarterly Comprehensive Income (Millions of US $) |
2024-06-30 |
$-19 |
2024-03-31 |
$-19 |
2023-12-31 |
$-19 |
2023-09-30 |
$-19 |
2023-06-30 |
$-21 |
2023-03-31 |
$-21 |
2022-12-31 |
$-22 |
2022-09-30 |
$-26 |
2022-06-30 |
$-21 |
2022-03-31 |
$-13 |
2021-12-31 |
$-8 |
2021-09-30 |
$-5 |
2021-06-30 |
$4 |
2021-03-31 |
$2 |
2020-12-31 |
$6 |
2020-09-30 |
|
2020-06-30 |
|
2020-03-31 |
|
2019-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Outpatient & Home Care |
$0.265B |
$0.000B |
atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
|